{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:33:51Z","timestamp":1789526031608,"version":"build-2803163510"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2016,4,27]],"date-time":"2016-04-27T00:00:00Z","timestamp":1461715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"HIV-NAT, The Thai Red Cross AIDS Research Centre"},{"name":"Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0154221","type":"journal-article","created":{"date-parts":[[2016,4,27]],"date-time":"2016-04-27T13:47:28Z","timestamp":1461764848000},"page":"e0154221","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study"],"prefix":"10.1371","volume":"11","author":[{"given":"Phairote","family":"Teeranaipong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunee","family":"Sirivichayakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suwanna","family":"Mekprasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pirapon June","family":"Ohata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anchalee","family":"Avihingsanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiat","family":"Ruxrungtham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Opass","family":"Putcharoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,4,27]]},"reference":[{"key":"ref1","unstructured":"Adolescents PoAGfAa (2015) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12981-015-0053-z","article-title":"Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014","volume":"12","author":"W Manosuthi","year":"2015","journal-title":"Thailand. AIDS Res Ther"},{"key":"ref3","year":"2013","unstructured":"(<year>2013<\/year>) C<chapter-title>onsolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach<\/chapter-title>. <publisher-loc>Geneva<\/publisher-loc>: <publisher-name>World Health Organization<\/publisher-name>"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(11)60992-6","article-title":"Rilpivirine: a step forward in tailored HIV treatment","volume":"378","author":"R Schrijvers","year":"2011","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2146\/ajhp110395","article-title":"Rilpivirine: a second-generation nonnucleoside reverse transcriptase inhibitor","volume":"69","author":"C James","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(11)60983-5","article-title":"Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial","volume":"378","author":"CJ Cohen","year":"2011","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(11)60936-7","article-title":"Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial","volume":"378","author":"JM Molina","year":"2011","journal-title":"Lancet"},{"key":"ref8","first-page":"268","article-title":"The role of rilpivirine in clinical practice: strengths and weaknesses of the new nonnucleoside reverse transcriptase inhibitor for HIV therapy","volume":"14","author":"A Imaz","year":"2012","journal-title":"AIDS Rev"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e31823df4da","article-title":"Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis","volume":"59","author":"L Rimsky","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/jac\/dks404","article-title":"Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor","volume":"68","author":"M Sharma","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/QAI.0000000000000017","article-title":"Characterization of HIV-1 Drug Resistance Development Through Week 48 in Antiretroviral Naive Subjects on Rilpivirine\/Emtricitabine\/Tenofovir DF or Efavirenz\/Emtricitabine\/Tenofovir DF in the STaR Study (GS-US-264-0110)","volume":"65","author":"DP Porter","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3851\/IMP1662","article-title":"Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials","volume":"15","author":"C Katlama","year":"2010","journal-title":"Antivir Ther"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1089\/aid.2009.0302","article-title":"Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies","volume":"26","author":"L Tambuyzer","year":"2010","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref14","unstructured":"WHO ResNet i-JM, Barcarolo J, Parkin N, de Oliveira T (analysis support), Bertagnolio S. (2012) WHO HIV drug resistance report 2012. WHO report: World Health Organization (WHO)."},{"key":"ref15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-151-4-200908180-00006","article-title":"Five-year outcomes of the China National Free Antiretroviral Treatment Program","volume":"151","author":"F Zhang","year":"2009","journal-title":"Ann Intern Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3851\/IMP1906","article-title":"Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens","volume":"16","author":"T Bunupuradah","year":"2011","journal-title":"Antivir Ther"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000331998","article-title":"The HIVdb system for HIV-1 genotypic resistance interpretation","volume":"55","author":"MW Tang","year":"2012","journal-title":"Intervirology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1506816","article-title":"Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection","volume":"373","author":"ISS Group","year":"2015","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1086\/510745","article-title":"Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails","volume":"44","author":"S Sungkanuparph","year":"2007","journal-title":"Clin Infect Dis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/QAD.0b013e32833677ac","article-title":"Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies","volume":"24","author":"J Vingerhoets","year":"2010","journal-title":"AIDS"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1128\/AAC.48.8.3122-3126.2004","article-title":"Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing","volume":"48","author":"SY Rhee","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1089\/aid.2011.0049","article-title":"Short communication prevalence of susceptibility to etravirine by genotype and phenotype in samples received for routine HIV type 1 resistance testing in the United States","volume":"27","author":"G Picchio","year":"2011","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/QAD.0b013e3283584500","article-title":"Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies","volume":"27","author":"L Anta","year":"2013","journal-title":"AIDS"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"474","DOI":"10.2174\/157016208785861230","article-title":"Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting","volume":"6","author":"S Sungkanuparph","year":"2008","journal-title":"Curr HIV Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0154221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T16:02:39Z","timestamp":1540310559000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0154221"}},"subtitle":[],"editor":[{"given":"Kok Keng","family":"Tee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,4,27]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,4,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0154221","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,27]]}}}